Prostate Cancer

Enzalutamide in prostate cancer: Hints of added benefit

Enzalutamide (trade name: Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic ...

Dec 06, 2013
popularity not rated yet | comments 0

World first trial to improve prostate cancer care

Researchers and clinicians from the University of Sydney and the Northern Sydney Cancer Centre are leading a world first clinical trial using a tracking system to improve prostate cancer radiotherapy treatment.

Nov 28, 2013
popularity not rated yet | comments 0

Bayer bids 1.8 bn euro for Norway's Algeta

German pharmaceutical group Bayer has made a bid for its Norwegian partner and competitor Algeta, specialised in cancer treatments, for 1.8 billion euro ($2.4 billion), the Nordic company said Tuesday.

Nov 26, 2013
popularity not rated yet | comments 0

Latest Spotlight News

Clearing cells to prevent cervical cancer

A study published online in the International Journal of Cancer earlier this month describes a novel approach to preventing cervical cancer based on findings showing successful reduction in the risk of cervical cancer after ...

What sign language teaches us about the brain

The world's leading humanoid robot, ASIMO, has recently learnt sign language. The news of this breakthrough came just as I completed Level 1 of British Sign Language (I dare say it took me longer to master signing ...